Latent TB infection treatment acceptance and completion in the United States and Canada

Chest

Volumn 137, Issue 2, 2010, Pages 401-409

  Horsburgh Jr , C Robert ^a   Goldberg, Stefan ^b   Bethel, James ^c   Chen, Shande ^d   Colson, Paul W ^e   Hirsch Moverman, Yael ^e   Hughes, Stephen ^f   Shrestha Kuwahara, Robin ^b   Sterling, Timothy R ^g   Wall, Kirsten ^h   Weinfurter, Paul ^b   McAuley, James ⁱ   Beison, Judith ⁱ   Wilson, Frank ⁱ   LeDoux, Cheryl ⁱ   Flood, Jennifer ⁱ   Sun, Sumi ⁱ   Ortega, Hugo ⁱ   Reves, Randall ⁱ   Blumberg, Henry M ⁱ   Tapia, Jane ⁱ   Wing, Jessie ⁱ   Jacobson, Sara ⁱ   Endyke Doran, Cara ⁱ   Etkind, Sue ⁱ   Sharnprapai, Sharon ⁱ   Sutherland, Wendy Mills ⁱ   Guled, Hodan ⁱ   Grabau, John ⁱ   Miranda, Wilson ⁱ   Royce, Rachel ⁱ   Dukes Hamilton, Carol ⁱ   Sanchez, Juani Munoz ⁱ   Haley, Connie ⁱ   Chavez Lindell, Tamara ⁱ   Graviss, Edward ⁱ   Chatterjee, Smita ⁱ   Griffith, David E ⁱ   Kimerling, Michael ⁱ   Tamhane, Ashutosh ⁱ   Naus, Monika ⁱ   Fitzgerald, Mark ⁱ   Nakajima, Maya ⁱ   Hershfield, Earl ⁱ   Roche, Barbara ⁱ   Selvam, Nandini ⁱ   Weis, Stephen ⁱ   Munguia, Guadalupe ⁱ   Yan, Jingsheng ⁱ   Venegas, Heidi L ⁱ   Brown, Sarah ⁱ   Jones, Mike ⁱ   more..

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c WESTAT   (United States)

^d UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANADA; CHILD; CONTROLLED STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE PERSONNEL; HEALTH SURVEY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NURSING HOME; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PRISON; REFUSAL TO PARTICIPATE; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; TREATMENT DURATION; TREATMENT REFUSAL; TUBERCULIN TEST; UNITED STATES;

EID: 76749101103     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-0394     Document Type: Article

References (30)

1. American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161(4 pt 2):S221-S247.
2. Centers for Disease Control (CDC). A strategic plan for the elimination of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep. 1989;38(16):269-272.
3. Geiter L. Ending Neglect. The Elimination of Tuberculosis in the United States. Washington, DC : National Academy Press; 2000.
4. Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L. Horsburgh CR; Tuberculosis Epidemiologic Studies Cosortium. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med. 2006;173(8):927-931.
5. Bennett DE, Courval JM, Onorato I, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med. 2008;177(3):348-355.
6. Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000;162(6):2033-2038.
7. Gilroy SA, Rogers MA, Blair DC. Treatment of latent tuberculosis infection in patients aged. or =35 years. Clin Infect Dis. 2000;31(3):826-829.
8. Sprinson JE, Flood J, Fan CS, et al. Evaluation of tuberculosis contact investigations in California. Int J Tuberc Lung Dis. 2003;7(12)(suppl 3):S363-S368.
9. Bock NN, Metzger BS, Tapia JR, Blumberg HM. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med. 1999;159(1):295-300.
10. Khoury SA, Theodore A, Platte VJ. Isoniazid prophylaxis in a slum area. Am Rev Respir Dis. 1969;99(3):345-353.
11. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis. 2008;12(11):1235-1254.
12. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med. 2003;168(4): 443-447.
13. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest. 2003;123(1):102-106.
14. Morisky DE, Ebin VJ, Malotte CK, Coly A, Kominski G. Assessment of tuberculosis treatment completion in an ethnically diverse population using two data sources. Implications for treatment interventions. Eval Health Prof. 2003;26(1): 43-58.
15. Jasmer RM, Saukkonen JJ, Blumberg HM, et al; Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002;137(8):640-647.
16. Shukla SJ, Warren DK, Woeltje KF, Gruber CA, Fraser VJ. Factors associated with the treatment of latent tuberculosis infection among health-care workers at a midwestern teaching hospital. Chest. 2002;122(5):1609-1614.
17. Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh CR Jr. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect. 2007;54(3):262-266.
18. Menzies D, Dion M-J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trail of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004; 170 (4):445-449.
19. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest. 2006;130(6):1712-1717.
20. Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006;166(17):1863-1870.
21. Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen JJ. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med. 2006;174(6):717-721.
22. Brick JM, Morganstein D. Computing Sampling Errors from Clustered Unequally Weighted Data Using Replication : WesVarPC. Bulletin of the International Statistical Institute. Proceedings, Book 1. 2007:479-482.
23. Maloney SA, Fielding KL, Laserson KF, et al. Assessing the performance of overseas tuberculosis screening programs: a study among US-bound immigrants in Vietnam. Arch Intern Med. 2006;166(2):234-240.
24. Cohen T, Murray M. Incident tuberculosis among recent US immigrants and exogenous reinfection. Emerg Infect Dis. 2005;11(5):725-728.
25. Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian refugees. A five-year surveillance study. Am Rev Respir Dis. 1988;137(4):805-809.
26. Cain KP, Benoit SR, Winston CA, Mac Kenzie WR. Tuberculosis among foreign-born persons in the United States. JAMA. 2008;300(4):405-412.
27. Goldberg SV, Wallace J, Jackson JC, Chaulk CP, Nolan CM. Cultural case management of latent tuberculosis infection. Int J Tuberc Lung Dis. 2004;8(1):76-82.
28. Whalen CC, Johnson JL, Okwera A, et al; Uganda-Case Western Reserve University Research Collaboration. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med. 1997;337(12):801-808.
29. Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med. 2006;173(8):922-926.
30. Tuberculosis Trials Consortium, Division of TB Elimination, Centers for Disease Control and Prevention. The Tuberculosis Trials Consortium: a model for clinical trials collaborations. Public Health Rep. 2001;116 (suppl 1):41-49.